Global Antibody Drug Conjugates Market, By Product (Adcetris, Kadcyla, and Other Product Types), By Application (Blood Cancer, Breast Cancer, Ovary Cancer, and Other Applications) By End User (Hospitals and Speciality Cancer Centers, Biotechnology and Pharmaceutical Companies, and Other End Users), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032
- Published date: Sept 2023
- Report ID: 102579
- Number of Pages: 373
- Format:
-
keyboard_arrow_up
-
-
- Takeda Pharmaceutical Company Limited
- Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- AstraZeneca Plc Company Profile
- Gilead Sciences, Inc.
- Astellas Pharma, Inc.
- Seagen, Inc.
- Daiichi Sankyo Company, Limited
- GlaxoSmithKline plc
- Adc Therapeutics Saa
- ImmunoGen Inc.
- Bayer AG Company Profile
- Novartis AG Company Profile
- Agensys Inc.
- Concortis Biotherapeutics
- NBE-Therapeutics
- Spirogen
- Oxford BioTherapeutics
- Other Key Players
- settingsSettings
Our Clients
- 102579
- Sept 2023
Trusted by more than 17382 organizations globally
✖
Request a Sample Report
We'll get back to you as quickly as possible
|
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
|---|---|---|---|
| e-Access | |||
| Report Library Access | |||
| Data Set (Excel) | |||
| Company Profile Library Access | |||
| Interactive Dashboard | |||
| Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
| Accessibility | 1 User | 2-5 User | Unlimited |
| Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
| Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
| Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |
